Citigroup Maintains Buy on WAVE Life Sciences, Lowers Price Target to $19

Benzinga Newsdesk www.benzinga.com Negative 48.5%

Neg 48.5% Neu 0% Pos 0%

Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $24 to $19.